Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

635 ARTÍCULOS , VIENDO DEL 121 AL 135

Adiponectin and Cognitive Decline

Rizzo MR, Fasano R, Paolisso G.

Int J Mol Sci. 2020 Mar 16;21(6):2010. doi: 10.3390/ijms21062010.

The neurocognitive and BDNF changes of multicomponent exercise for community-dwelling older adults with mild cognitive impairment or dementia: a systematic review and meta-analysis

Wang X, Wang H, Ye Z, Ding G, Li F, Ma J, Hua W.

Aging (Albany NY). 2020 Mar 19;12(6):4907-4917. doi: 10.18632/aging.102918. Epub 2020 Mar 19.

Blood fatty acids in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review

Hosseini M, Poljak A, Braidy N, Crawford J, Sachdev P.

Ageing Res Rev. 2020 Jul;60:101043. doi: 10.1016/j.arr.2020.101043. Epub 2020 Mar 16.

Terms and Measures of Cognitive Health Associated With Dementia and Alzheimer's Disease: A Scoping Review

Quinn K, Miyawaki CE, Croff R, Vogel MT, Belza B, Souza AM, Liu M, Edwards VJ, Friedman DB.

Res Aging. 2020 Jun-Jul;42(5-6):174-185. doi: 10.1177/0164027520911284. Epub 2020 Mar 20.

Disentangling Heterogeneity in Alzheimer's Disease and Related Dementias Using Data-Driven Methods

Habes M, Grothe MJ, Tunc B, McMillan C, Wolk DA, Davatzikos C.

Biol Psychiatry. 2020 Jul 1;88(1):70-82. doi: 10.1016/j.biopsych.2020.01.016. Epub 2020 Jan 31.

Pathological Continuum From the Rise in Pulse Pressure to Impaired Neurovascular Coupling and Cognitive Decline

de Montgolfier O, Thorin-Trescases N, Thorin E.

Am J Hypertens. 2020 Apr 29;33(5):375-390. doi: 10.1093/ajh/hpaa001.

Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

Panza F, Lozupone M, Seripa D, Daniele A, Watling M, Giannelli G, Imbimbo BP.

Nat Rev Neurol. 2020 Apr;16(4):213-228. doi: 10.1038/s41582-020-0330-x. Epub 2020 Mar 23.

18F-FDG PET/CT Brain in a Case of Agrammatic/Nonfluent Variant of Primary Progressive Aphasia (Broca's Aphasia)

Kousik V, Mittal BR, Kumar R, Singh H, Goyal M.

Clin Nucl Med. 2020 May;45(5):e258-e259. doi: 10.1097/RLU.0000000000003008.

The quest for dementia prevention does not include an aspirin a day

Knopman DS, Petersen RC.

Neurology. 2020 Jul 21;95(3):105-106. doi: 10.1212/WNL.0000000000009278. Epub 2020 Mar 25.

Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline

Ryan J, Storey E, Murray AM, Woods RL, Wolfe R, Reid CM, Nelson MR, Chong TTJ, Williamson JD, Ward SA, Lockery JE, Orchard SG, Trevaks R, Kirpach B, Newman AB, Ernst ME, McNeil JJ, Shah RC; ASPREE Investigator Group.

Neurology. 2020 Jul 21;95(3):e320-e331. doi: 10.1212/WNL.0000000000009277. Epub 2020 Mar 25.

CE: Acute Care for Patients with Dementia

Zonsius MC, Cothran FA, Miller JM.

Am J Nurs. 2020 Apr;120(4):34-42. doi: 10.1097/01.NAJ.0000660024.45260.1a.

Cost-effectiveness of a non-pharmacological treatment vs. "care as usual" in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial

Steinbeisser K, Schwarzkopf L, Graessel E, Seidl H.

Eur J Health Econ. 2020 Aug;21(6):825-844. doi: 10.1007/s10198-020-01175-y. Epub 2020 Mar 26.

One-Year Evaluation of a Targeted Medication Therapy Management Intervention for Older Adults

Martinez AI, Abner EL, Jicha GA, Rigsby DN, Eckmann LC, Huffmyer MJ, Moga DC.

J Manag Care Spec Pharm. 2020 Apr;26(4):520-528. doi: 10.18553/jmcp.2020.26.4.520.

Cerebral Small Vessel Disease

Rost NS, Etherton M.

Continuum (Minneap Minn). 2020 Apr;26(2):332-352. doi: 10.1212/CON.0000000000000841.

Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant

Gonçalves ECD, Baldasso GM, Bicca MA, Paes RS, Capasso R, Dutra RC.

Molecules. 2020 Mar 29;25(7):1567. doi: 10.3390/molecules25071567.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias